Skip to main content
Premium Trial:

Request an Annual Quote

CeMines Estonian Subsidiary Co-Founds Cancer Diagnostics and Therapeutics Firm

NEW YORK, Jan. 11 (GenomeWeb News) - CeMines Estonia OU, a subsidiary of CeMines International, has co-founded VTAK, a privately held company focused on researching and commercializing cancer diagnostics and therapeutics, CeMines said yesterday.

 

VTAK was founded in conjunction with the Estonian government, as well as several academic institutions and companies including Tallinn Technical University; Helsinki Yliopiston Saatio; Regional Hospital of North Estonia; ProSyntest AS; Kevelt AS; CeleCure AS; Trial Form Support AB; and InBio OU.

 

Golden, Colo.-based CeMines is the only US-based company participating in VTAK, the company said. CeMines created the CeMines International operating division and its Estonian subsidiary in December.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.